Market Cap (In USD)
2.84 Billion
Revenue (In USD)
-
Net Income (In USD)
-100.16 Million
Avg. Volume
1.21 Million
- Currency
- USD
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 8.64-38.12
- PE
- -
- EPS
- -
- Beta Value
- 0.153
- ISIN
- US28036F1057
- CUSIP
- 28036F105
- CIK
- 1710072
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dr. Kevin Koch Ph.D.
- Employee Count
- -
- Website
- https://www.edgewisetx.com
- Ipo Date
- 2021-03-26
- Details
- Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has completed Phase 1 clinical trial. It develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.
More Stocks
-
GTLL
-
ARHSArhaus, Inc.
ARHS
-
UMIYAUmiya Tubes Limited
UMIYA
-
FINMFLeonardo S.p.a.
FINMF
-
APP
-
CTKB
-
KHADIMKhadim India Limited
KHADIM
-
SULA